HMGCR and breast cancer: The inhibitory effect on cell migration is comparable with that treated with atorvastatin, an inhibitor of hydroxylmethylglutaryl co-enzyme A (HMG-CoA) reductase that blocks the Hippo-YAP/TAZ pathway in breast cancer cells [21, 34, 35].